Emcitate (tiratricol)

MCT8 deficiency

Manufacturer: Egetis Therapeutics
Regulatory submission: NDA submitted January 2026 and approved September 2026
Launch: Anticipated eight to ten weeks after the September 2026 approval
Last updated: September 29, 2026

Section

Product information and disease description Place of product in therapy Disease description

Burden of MCT8 deficiency

12 evidence topics · 8 sources

Economic impact of MCT8 deficiency on families

No evidence found.